Kenneth J. Eilertsen
Gründer bei Infigen, Inc.
Profil
Kenneth J.
Eilertsen is the founder of NuPotential, Inc., a company founded in 2007.
He held the title of President & Director from 2013 to 2015.
Dr. Eilertsen is also the founder of Infigen, Inc...
He has worked as a Research Scientist at Johnson & Johnson and as a Faculty Member at Pennington Biomedical Research Center.
Dr. Eilertsen obtained his doctorate degree from Florida State University in 1994.
Aktive Positionen von Kenneth J. Eilertsen
Unternehmen | Position | Beginn |
---|---|---|
Infigen, Inc.
Infigen, Inc. Miscellaneous Commercial ServicesCommercial Services Infigen, Inc. provides biotechnology research services. It develops xenotransplantation technology to allow animal organs to be transplanted into humans. The company's products are used in various therapeutic applications including surgery, trauma, cancer therapy, urinary & fecal incontinence, and cosmetic reconstruction. The firm was founded in 1997 and is headquartered in DeForest, WI | Gründer | 06.11.2013 |
Ehemalige bekannte Positionen von Kenneth J. Eilertsen
Unternehmen | Position | Ende |
---|---|---|
JOHNSON & JOHNSON | Corporate Officer/Principal | - |
Pennington Biomedical Research Center
Pennington Biomedical Research Center Miscellaneous Commercial ServicesCommercial Services Pennington Biomedical Research Center is a medical research center affiliated with Louisiana State University. The center is located in state-of-the-art research facilities on a 222-acre campus. The non-profit company is based in Baton Rouge, LA. The center conducts basic, clinical, and population research to understand the triggers of obesity, diabetes, cardiovascular disease, cancer, and dementia. With over 500 employees, the research enterprise includes a network of 40 clinics, research laboratories, and 13 highly specialized core service facilities. | Corporate Officer/Principal | - |
NuPotential, Inc.
NuPotential, Inc. Pharmaceuticals: MajorHealth Technology NuPotential, Inc. engages in the discovery and development of novel drugs that modulate epigenetic targets and their processes for the treatment of cancer. It specializes in producing de-differentiated cell lines suitable for re-differentiation into multiple lineages and somatic cell nuclear transfers. The company was founded by Kenneth J. Eilertsen and Charles Oehler in 2007 and is headquartered in Baton Rouge, LA. | Gründer | - |
Ausbildung von Kenneth J. Eilertsen
Florida State University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
JOHNSON & JOHNSON | Health Technology |
Private Unternehmen | 3 |
---|---|
Infigen, Inc.
Infigen, Inc. Miscellaneous Commercial ServicesCommercial Services Infigen, Inc. provides biotechnology research services. It develops xenotransplantation technology to allow animal organs to be transplanted into humans. The company's products are used in various therapeutic applications including surgery, trauma, cancer therapy, urinary & fecal incontinence, and cosmetic reconstruction. The firm was founded in 1997 and is headquartered in DeForest, WI | Commercial Services |
NuPotential, Inc.
NuPotential, Inc. Pharmaceuticals: MajorHealth Technology NuPotential, Inc. engages in the discovery and development of novel drugs that modulate epigenetic targets and their processes for the treatment of cancer. It specializes in producing de-differentiated cell lines suitable for re-differentiation into multiple lineages and somatic cell nuclear transfers. The company was founded by Kenneth J. Eilertsen and Charles Oehler in 2007 and is headquartered in Baton Rouge, LA. | Health Technology |
Pennington Biomedical Research Center
Pennington Biomedical Research Center Miscellaneous Commercial ServicesCommercial Services Pennington Biomedical Research Center is a medical research center affiliated with Louisiana State University. The center is located in state-of-the-art research facilities on a 222-acre campus. The non-profit company is based in Baton Rouge, LA. The center conducts basic, clinical, and population research to understand the triggers of obesity, diabetes, cardiovascular disease, cancer, and dementia. With over 500 employees, the research enterprise includes a network of 40 clinics, research laboratories, and 13 highly specialized core service facilities. | Commercial Services |